2026-05-10T16:25:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/235182024-11-28T17:38:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16984col_20.500.12105_16985

00925njm 22002777a 4500 dc Barretina-Ginesta, Maria Pilar author Quindós, María author Alarcón Company, Jesús author Esteban, Carmen author Gaba Garcia, Lydia author Gomez, Cesar author Perez Fidalgo, Jose Alejandro author Romero, Ignacio author Santaballa, Ana author Rubio-Perez, Maria Jesús author 2022-04 Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209-249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice. Barretina-Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, et al. SEOM-GEICO clinical guidelines on endometrial cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):625-34. 10.1007/s12094-022-02799-7 1699-3055 1699-048X Clinical & Translational Oncology https://hdl.handle.net/20.500.13003/19815 35312947 L2015382411 2-s2.0-85126803367 https://hdl.handle.net/20.500.12105/23518 771319500001 Endometrial cancer Guideline Diagnosis Treatment SEOM-GEICO clinical guidelines on endometrial cancer (2021)